Recent Event
DATE2026.09.23
VIEWS396
The seminar brought together around 140 R&D and business development (BD) professionals from biotech companies to explore how early-stage research outcomes can be developed into assets with global licensing potential. Speakers also shared real-world experiences and strategies for aligning R&D with global partnering needs.
The program covered:
- From R&D to Global Licensing: Experts discussed why demonstrating clinical potential and development feasibility is becoming increasingly important in global drug development, with a focus on generating differentiated data and identifying the potential for success in humans at an early stage.
- Real-World Development Strategies: Speakers shared practical approaches, including translational research to identify suitable patient populations and reduce development risks, as well as the use of AI and human data through digital twins to predict drug responses before clinical development.
- Bridging R&D and BD: The seminar highlighted the growing need for closer collaboration between R&D and BD teams. Understanding what global partners are looking for and reflecting those needs in research and clinical strategies can help create greater strategic value for drug assets.
Speakers emphasized that strong development strategies should go beyond simply advancing a candidate to the next stage.
Early consideration of factors such as mechanism of action in humans, target patient populations, clinical differentiation, and regulatory pathways can help strengthen the asset’s value for global partnering.
The seminar was followed by an evening networking session, providing participants with an opportunity to exchange insights, share industry experiences, and build connections with fellow R&D and BD professionals.
More Dealmaker Academy programs will continue, so stay tuned!
